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Mini-Abstract 
Of measures of the systemic inflammatory response, the modified Glasgow 
Prognostic Score has been most extensively validated in cancer.  The present study examined 
its clinical utility in a large cohort of patients undergoing potentially curative resection of 
colorectal cancer. 
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Abstract 
Objective 
The present study aims to examine the clinical utility of the combination of TNM stage and 
modified Glasgow Prognostic Score (mGPS) in patients undergoing potentially curative 
resection of colorectal cancer (CRC). 
Background 
Of measures of the systemic inflammatory response, the mGPS has been most extensively 
validated in patients with cancer.   
Methods 
Data from 1000 consecutive patients undergoing potentially curative CRC resection from a 
single institution (January 1997 to May 2013) were included.  The relationship between 
mGPS (0 – CRP ≤10mg/L, 1- CRP >10mg/L and albumin ≥35g/L, 2- CRP >10mg/L and 
albumin <35g/L), TNM stage and cancer-specific survival (CSS) and overall survival (OS) 
was examined using Kaplan-Meier and multivariate Cox regression analysis. 
Results 
An mGPS of 0, 1 and 2 was observed in 63%, 21% and 16% of patients. Median follow-up 
was 56 months (IQR: 28-107 months).  TNM and mGPS were independently associated with 
CSS and OS (all P<0.001).  In all patients, TNM and mGPS stratified five-year CSS and OS 
from 97% and 87% (stage I, mGPS=0) to 32% and 26% (stage III, mGPS=2) respectively.  In 
patients undergoing elective resection of colon cancer (n=575), five-year CSS and OS ranged 
from 100% and 87% (stage I, mGPS=0) to 37% and 30% (stage III, mGPS=2), respectively.   
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Conclusions 
The present study shows how the combination of TNM and mGPS effectively stratifies 
outcome in patients undergoing potentially curative resection of CRC.  These data support 
routine staging of both the tumor and the host in patients with CRC. 
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INTRODUCTION 
 Colorectal cancer is the third most common cancer in the Western World and the 
second most common cause of cancer death.1  Currently the need for adjuvant therapy is 
primarily based on pathological staging of the resected tumor using TNM criteria.2  However, 
such a scheme may fail to accurately distinguish patients at high risk of recurrence and cancer 
death, particularly in the context of lymph node negative disease.3  
Characteristics pertaining to the host, such as emergency presentation,4 are also 
independently associated with poorer oncological outcome. Furthermore, the presence of an 
elevated systemic inflammatory response, as evidenced by changes in circulating acute phase 
proteins or myeloid cells, is an important unifying host characteristic and has been 
consistently associated with reduced survival, independent of stage, across a number of 
cancers including colorectal cancer.5, 6  Systemic inflammation-based prognostic scores, such 
as the modified Glasgow Prognostic Score (mGPS) and the neutrophil:lymphocyte ratio 
(NLR) have been repeatedly reported to have prognostic value in a variety of operable 
cancers.5, 6  Of these, the mGPS, a cumulative score based on the presence of an elevated 
serum C-reactive protein (CRP) and decreased serum albumin, has been reported to have 
superior prognostic value compared to the NLR in patients with operable colorectal cancer.7-
10 
Although the prognostic value of the mGPS has been widely reported, how it might 
be incorporated into the existing TNM-based staging of colorectal cancer, and how it might 
be implemented in the context of routine clinical practice and clinical trials is not clear.  In 
the present study, the clinical utility of assessment of the systemic inflammatory response, 
utilizing pre-operative mGPS, was examined in a large cohort of patients undergoing 
potentially curative resection of colorectal cancer.  
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PATIENTS AND METHODS 
 Patients were identified from a prospectively collected and maintained database of 
elective and emergency colorectal cancer resections undertaken in a single surgical unit at 
Glasgow Royal Infirmary.  Consecutive patients who had pre-operative measurement of 
serum CRP and serum albumin within 30 days prior to surgery and, who on the basis of 
preoperative abdominal computed tomography and laparotomy findings were considered to 
have undergone potentially curative resection for colorectal adenocarcinoma without distant 
metastases between January 1997 and May 2013 were included.  Patients with inflammatory 
bowel disease-related cancer, who underwent resection with palliative intent or local 
resection only, or had not had pre-operative measurement of CRP or albumin, were excluded.   
 Tumors were staged using the fifth edition of the tumor, node and metastases 
classification,2 with additional data taken from pathological reports issued following 
resection.  Following surgery, all patients were discussed at a colorectal multidisciplinary 
meeting involving surgeons, oncologists, radiologists and pathologists with a colorectal 
cancer special interest; patients with stage III or high-risk stage II disease and no significant 
comorbidities precluding chemotherapy use were offered primarily 5-fluorouracil-based 
adjuvant chemotherapy on the basis of current guidelines at the time. 
 Pre-operative serum CRP and albumin were recorded prospectively.  Patients 
undergoing elective resection had serum CRP and albumin concentrations measured routinely 
within 30 days prior to elective surgery.  In patients undergoing emergency resection, CRP 
and albumin measured on admission were recorded.  The mGPS was constructed as 
previously described;5 patients with a CRP ≤10mg/L were allocated a score of 0, a CRP 
>10mg/L and albumin ≥35g/L a score of 1, and a CRP >10mg/L and albumin <35g/L a score 
of 2. 
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 Patients were routinely followed up for five years following surgery. Date and cause 
of death was crosschecked with the cancer registration system and the Registrar General 
(Scotland).  Death records were complete until 31st March 2014 that acted as the censor date.  
Cancer-specific survival was measured from date of surgery until date of death from 
recurrent or metastatic colorectal cancer.  Overall survival was measured until the date of 
death from any cause. 
 The relationship between clinicopathological characteristics, pre-operative mGPS and 
five and ten-year survival was examined using Kaplan-Meier log-rank survival analysis and 
univariate Cox proportional hazards regression to calculate hazard ratios (HRs) and 95% 
confidence intervals (95% CI).  Variables statistically significant on univariate analysis were 
subsequently entered into a multivariate model using a backwards conditional method.  The 
relationship between mGPS and clinicopathological characteristics was examined using the χ2 
method for linear trend.  A P-value ≤0.05 was considered statistically significant.  All 
analyses were performed using SPSS version 22.0 (IBM SPSS, IL, USA).  The West of 
Scotland Research Ethics Committee approved the study. 
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RESULTS 
 One thousand patients who underwent potentially curative resection of colorectal 
cancer were studied.  Clinicopathological characteristics are shown in Table 1.  Data on 
neoadjuvant therapy, adjuvant therapy and tumor differentiation were missing in 19, two and 
10 patients respectively.  Two-thirds of patients were older than 65 at time of surgery, 55% 
were male and over 90% of patients underwent elective resection.  Two thirds of patients 
underwent resection of colon cancer.  Ninety-three patients with rectal cancer and five 
patients with colon cancer received neoadjuvant therapy prior to surgery; of these, thirteen 
patients with rectal cancer had pathological confirmation of stage 0 disease (complete 
pathological response).  Overall, 15% of patients had stage I disease, 46% had stage II 
disease and 38% had stage III disease.  A quarter of patients received adjuvant chemotherapy 
following surgery; 16% of patients with stage II disease and 45% of patients with stage III 
disease received adjuvant therapy.   
Thirty-seven percent of patients had CRP >10mg/L and 26% had an albumin <35g/L 
prior to surgery.  Almost two thirds of patients were mGPS=0, whereas 21% and 16% were 
mGPS=1 and mGPS=2 respectively.  An elevated mGPS was associated with advancing age, 
emergency presentation (both ≤0.001), less frequent use of neoadjuvant therapy (P<0.05), 
colonic primary, advancing T stage, advancing TNM stage, poor tumor differentiation, 
surgical margin involvement, peritoneal involvement and tumor perforation (all P≤0.001). 
 The median follow-up of survivors was 56 months (range 10-206 months; 
interquartile range 28-107 months), with 242 colorectal cancer-related deaths and 193 non-
cancer deaths.  Cancer-specific survival at five and ten years was 75% and 67% respectively, 
and overall survival at five and ten years was 64% and 43%.  The relationship between 
clinicopathological characteristics, pre-operative mGPS and survival is shown in Table 2.  
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The following clinicopathological characteristics were associated with reduced cancer-
specific survival on univariate analysis: mGPS (P<0.001), advancing age (P<0.01), 
emergency presentation (P<0.01), T stage (P<0.001), N stage (P<0.001), poor differentiation 
(P<0.01), venous invasion (P<0.001), margin involvement (P<0.001) and peritoneal 
involvement (P<0.001).  On multivariate survival analysis, mGPS was associated with 
reduced cancer-specific survival (HR 1.28 P=0.003), independent of age (P<0.01), T stage 
(P<0.001), N stage (P<0.001) and margin involvement (P<0.001).  Poor differentiation and 
venous invasion showed a trend towards reduced survival on multivariate analysis (P=0.086 
and P=0.094, respectively), whereas emergency presentation, peritoneal involvement and 
tumor perforation were not associated with survival.   
The following clinicopathological characteristics were associated with reduced overall 
survival on univariate analysis: mGPS (P<0.001), advancing age (P<0.001), emergency 
presentation (P<0.05), no adjuvant therapy (P<0.05), T stage (P<0.001), N stage (P<0.001), 
poor differentiation (P=0.001), venous invasion (P<0.01), margin involvement (P<0.001) and 
peritoneal involvement (P<0.001).  On multivariate analysis mGPS was associated with 
reduced overall survival (HR 1.28, P<0.001), independent of age (P<0.001), adjuvant 
therapy use (P<0.05), T stage (P<0.05), N stage (P<0.001), differentiation (P<0.05) and 
margin involvement (P<0.001).  Venous invasion showed a trend towards reduced overall 
survival (P=0.066), whereas emergency presentation, peritoneal involvement and tumor 
perforation were not associated with survival. 
The relationship between pre-operative mGPS, TNM stage and cancer-specific and 
overall survival is shown in Figure 1 and Table 3.  Cancer-specific survival at five years 
varied from 100% in patients with stage 0 colorectal cancer to 61% in patients with stage III 
disease and from 80% in patients with mGPS=0 to 61% in patients with mGPS=2. When 
combined, cancer-specific survival at five years varied from 100% in patients with stage 0 
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disease and mGPS=0, to 32% in patients with stage III disease and mGPS=2 (P<0.001).  A 
similar relationship between TNM stage, mGPS and ten-year cancer-specific survival was 
also observed; whereas survival ranged from 100% to 52% and from 70% to 52% with TNM 
stage or mGPS alone, the combination of TNM and mGPS stratified ten-year survival from 
100% (TNM 0, mGPS=0) to 32% (TNM III, mGPS=2).  The synergistic nature of the 
relationship between TNM stage and mGPS is, for example, shown for TNM stage III in 
Figure 2a (P<0.001). 
Overall survival at five years varied from 92% (stage 0) to 51% (stage III) and from 
70% (mGPS=0) to 46% (mGPS=2).  Ten year overall survival varied from 92% (stage 0) to 
35% (stage III) and from 49% (mGPS=0) to 30% (mGPS=2).  Utilizing both TNM stage and 
mGPS, five-year overall survival ranged from 92% (TNM 0, mGPS=0) to 26% (stage III, 
mGPS=2) and ten-year overall survival ranged from 92% (TNM 0, mGPS=0) to 17% (TNM 
III, mGPS=2) (P<0.001).  The synergistic effect of the combination of TNM stage and mGPS 
on overall survival is again evident in Figure 2b (P<0.001).  
As mGPS was associated with emergency resection and a colonic primary, to control 
for any confounding of these variables the relationship between TNM stage, mGPS and 
survival was examined for 575 patients undergoing elective resection of colon cancer.  In 
patients undergoing elective resection of colon cancer, an elevated mGPS was associated 
with advancing age, advancing T stage and TNM stage, poor differentiation, surgical margin 
and peritoneal involvement and tumor perforation (Table 4).  The median follow-up of 
survivors was 56 months (range 10-206 months; interquartile range 27-107 months), with 122 
cancer-related deaths and 124 non-cancer deaths.  Cancer-specific and overall survival was 
79% and 66% respectively at five years and 70% and 43% at ten years. On multivariate 
analysis, mGPS was associated with reduced cancer-specific survival (HR 1.61, 95% CI 1.28-
2.02, P<0.001), independent of age (P<0.05), T stage (P=0.001),  N stage (P<0.001), and 
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reduced overall survival (HR 1.52, 95% CI 1.29-1.78, P<0.001), independent of age 
(P<0.001), no adjuvant therapy (P<0.05), N stage (P<0.001) and margin involvement 
(P=0.001) (Supplementary Table 1).  Venous invasion, peritoneal involvement and tumor 
perforation were not associated with cancer-specific or overall survival on multivariate 
analysis. 
In patients undergoing elective resection of colon cancer, cancer-specific survival at 
five years ranged from 96% in patients with stage I disease to 63% in patients with stage III 
disease and from 86% in patients with mGPS=0 to 64% in patients with mGPS=2 (both 
P≤0.001) (Figure 3a-b, Table 5a).  Cancer-specific survival at ten years ranged from 96% 
(stage I) to 54% (stage III) and from 76% (mGPS=0) to 49% (mGPS=2).  The combination of 
TNM stage and mGPS stratified both five and ten-year cancer-specific survival from 100% 
(stage I, mGPS=0) to 37% (stage III, mGPS=2) (P<0.001).  Overall survival ranged from 
79% (stage I) to 54% (stage III) and from 75% (mGPS=0) to 46% (mGPS=2) at five years, 
and from 44% (stage I) to 38% (stage III) and 54% (mGPS=0) to 24% (mGPS=2) at ten years 
(both P≤0.001) (Figure 3c-d, Table 5b).  The combination of TNM stage and mGPS stratified 
overall survival at five years from 87% (stage I, mGPS=0) to 30% (stage III, mGPS=2) and at 
ten years  from 53% (stage I, mGPS=0) to 17% (stage III, mGPS=2) ( P<0.001). 
Subgroup analysis was subsequently performed to examine the relationship between 
mGPS, use of adjuvant chemotherapy and cancer-specific survival of 205 patients undergoing 
elective resection of stage III colon cancer.  Use of adjuvant chemotherapy was associated 
with younger age (P<0.001), less advanced T stage and a lower mGPS (both P<0.05) but no 
other clinicopathological characteristics.  The median follow-up of survivors was 61 months 
(range 11-205 months; interquartile range 31-107 months), with 71 cancer-related deaths.  
Cancer-specific survival was 79% at five years and 64% at ten years for patients with stage 
III colon cancer who received adjuvant chemotherapy, compared to 51% and 47% 
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respectively for patients who did not receive adjuvant therapy (P=0.002) (Table 6a).  The 
mGPS stratified survival of patients with stage III colon cancer irrespective of adjuvant 
therapy status;  for example, five-year survival varied from 91% (mGPS=0) to 61% 
(mGPS=1) for patients who received adjuvant therapy (P=0.003), and varied from 60% 
(mGPS=0) to 34% (mGPS=2) for patients who did not receive adjuvant therapy (P=0.114).  
Furthermore, whereas use of adjuvant therapy was associated with increased survival in 
patients with mGPS=0 (P=0.003), it was not associated with improved survival in patients 
with an elevated mGPS (P=0.357). 
Finally, subgroup analysis was performed to examine the relationship between mGPS, 
ASCO high-risk pathological criteria (presence of a T4 tumor, lymph node yield <10 nodes, 
poor tumor differentiation, tumor perforation or venous invasion) and cancer-specific 
survival of 239 patients undergoing elective resection of stage II colon cancer without 
subsequent adjuvant therapy.  The median follow-up of survivors was 63 months (range 10-
205 months; interquartile range 28-111 months), with 41 cancer-related deaths.  Five and ten-
year survival of patients with no high-risk pathological characteristics was 91% and 85% 
respectively, compared to 83% and 70% for patients with one or more high-risk characteristic 
(P=0.138) (Table 6b).  An elevated mGPS was associated with reduced survival of patients 
with both low and high-risk stage II colon cancer; ten-year survival of patients with low-risk 
disease was stratified from 88% (mGPS=0) to 68% (mGPS=2) (P=0.035), and ten-year 
survival of patients with high-risk disease varied from 71% to 51% (P=0.042). 
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DISCUSSION 
The results of the present study show how the combination of TNM and mGPS 
effectively stratifies outcome in patients undergoing potentially curative resection of 
colorectal cancer.  These data support the routine staging of both the tumor and the host 
systemic inflammatory response in patients with colorectal cancer. 
In the present study, an increasing mGPS was associated with the presence of high-
risk clinicopathological characteristics pertaining to both the host and the tumor.  Even so, the 
pre-operative mGPS was prognostic independent of TNM stage and routinely reported 
adverse tumour characteristics, such as peritoneal involvement and tumor perforation.  
Furthermore, although associated with emergency presentation and a colonic primary, which 
may potentially reflect site-specific tumor heterogeneity,11 it was of interest that the mGPS 
retained independent prognostic utility in the context of elective resection of colon cancer.  
Indeed, the combination of TNM stage and mGPS increased the range of survival compared 
to either TNM or mGPS alone.  For example, whereas five-year cancer-specific survival of 
all patients undergoing elective resection of stage III colon cancer was 63%, the addition of 
mGPS stratified survival from 75% to 37%.  Furthermore, within stage II disease, it was 
possible to identify a fifth of patients undergoing resection at higher risk than that afforded by 
TNM criteria alone. 
The present study was able to provide further insight regarding the relationship 
between systemic inflammatory responses and use of adjuvant chemotherapy for stage III 
colon cancer.  Patients with an elevated mGPS prior to elective resection were less likely to 
receive adjuvant therapy.  At the time of data collection, however, it was unlikely to have 
been a factor in the multidisciplinary team’s decision to recommend chemotherapy.  
Furthermore, although an elevated mGPS was associated with advancing age, over 40% of 
patients who did not receive chemotherapy were younger than 75 at time of surgery.  With 
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such observational studies, there is a concern that one might be examining a population with 
an associated but unrelated (to cancer) chronic inflammatory state which also was associated 
with a lower rate of adjuvant therapy.  However, the common chronic inflammatory 
conditions, such as rheumatoid arthritis, do not normally preclude adjuvant chemotherapy.  It 
is therefore of interest that an elevated mGPS has previously been associated with co-morbid 
status12, 13 and the presence of post-operative infectious complications.14  However, although 
both may preclude use of adjuvant chemotherapy and explain the present inverse association 
between mGPS and use of adjuvant therapy,15 it is important to note that the relationship 
between mGPS and oncological outcome has previously been shown to be independent of 
underlying patient co-morbidity. 13, 16  
Of interest, the mGPS stratified the survival of patients who received adjuvant 
chemotherapy following resection of stage III colon cancer.  Although the present analysis 
must be interpreted with caution, it is consistent with previous reports.5  Indeed in the present 
study, although patients with mGPS=0 had a 50% relative increase in survival at five years 
with adjuvant therapy, patients with mGPS≥1 appeared to derive no benefit.  The underlying 
mechanism responsible for this lack of benefit is unclear; whereas it may be indicative of 
reduced tolerance to chemotherapy leading to subsequent dose reduction or cessation of 
treatment,17 it may simply represent a lack of efficacy in the systemically inflamed patient.  
Certainly, although secondary analyses of reported trials of adjuvant chemotherapy may 
provide further insight, it is clear that future studies of adjuvant therapies should incorporate 
assessment of the pre-operative systemic inflammatory response. 
Although there is clear rationale for the use of adjuvant chemotherapy in patients with 
stage III colon cancer, the post-operative management of lymph node negative disease is 
problematic.3  Other high-risk pathological characteristics, such as the presence of venous 
invasion, have been shown to effectively stratify outcome within TNM and may predict need 
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for adjuvant therapy.18  However, the recent inclusion of venous invasion, alongside other 
high risk pathological characteristics as additional prognostic factors in tumor staging does 
not negate the utility of host characteristics, such as the mGPS, in the effective stratification 
of outcome.  Indeed, in the present study, patients with mGPS=2 undergoing elective 
resection for otherwise low-risk stage II colon cancer had five and ten-year survival 
comparable to that of patients with stage III disease.  Although the small number of patients 
receiving adjuvant therapy for stage II colon cancer precluded meaningful analysis in the 
present study, whether the mGPS may aid in the selection of patients with stage II colon 
cancer likely to benefit from adjuvant therapy would be of considerable interest.  
Furthermore, whereas assessment of pathological characteristics are often subjective and may 
be underreported,19 the components of the mGPS, CRP and albumin, are objectively 
measured and routinely available.  
 The present study was limited by its single centre nature; however this was a large, 
prospectively collected cohort of patients.  Although a population whose mGPS reverted to 
normal following surgery would be of interest, the majority of patients do not, in terms of 
their mGPS, change their inflammatory state.  Indeed of those patients with an elevated 
mGPS, up to 80% may remain systemically inflamed following potentially curative resection 
of colorectal cancer.9  As such, any changes to the operative and peri-operative management 
of patients over the time period studied, for example the introduction of enhanced recovery 
protocols to our centre in 2011, are unlikely to have had a significant effect on the mGPS.  
Furthermore, the small number of patients undergoing resection for stage I colon cancer and 
patients with rectal cancer precluded meaningful analysis within these subsets.  Given that 
earlier stage disease is likely to predominate in the context of colorectal cancer screening 
programmes,20 whether mGPS may aid in the decision between local excision and formal 
resection in patients presenting with early stage disease would be an important area for future 
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research.  Finally, as mGPS was only recorded prior to surgery, it was not possible to 
examine the impact of neoadjuvant chemoradiotherapy on the mGPS of patients with rectal 
cancer.  This would also be of considerable interest. 
Although representing only “the tip of a far larger iceberg” in inflammation-
associated tumor progression and dissemination,21 the use of routinely available biomarkers, 
such as the mGPS, allows us to utilise our current understanding of the systemic 
inflammatory responses in patients with cancer.  This has several far-reaching implications 
for clinical practice.  As demonstrated, alongside guiding long-term prognosis, the 
incorporation of the mGPS into routine assessment may also identify patients less likely to 
tolerate, or benefit from, adjuvant systemic therapy.  Furthermore, routine use of the mGPS 
may also direct future therapeutic strategies, targeted at the systemic inflammatory response 
itself.  Indeed, it is now appreciated that systemic inflammation is complicit in cancer 
cachexia,22 and may be attenuated by the use of non-steroidal anti-inflammatory drugs 
(NSAIDs).23  A similar scheme may also be applied to patients undergoing potentially 
curative surgery.  For example, in patients with stage III disease, those with mGPS=0 may 
benefit from adjuvant chemotherapy alone, whereas those with an elevated mGPS may also 
benefit from the addition of an anti-inflammatory agent, such as aspirin or other NSAID.24, 25  
Certainly, it is clear that randomised controlled trials, incorporating both routine assessment 
of the systemic inflammatory response and use of anti-inflammatory agents, are required. 
In conclusion, the mGPS provides complimentary prognostic information to current 
TNM-based staging and may also aid in directing future therapeutic strategies, targeting the 
systemic inflammatory response.  Given that the combination of TNM stage and the mGPS 
are routinely available worldwide, this staging system for patients undergoing potentially 
curative resection of colorectal cancer has much to commend it. 
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Figure 1. A, Relationship between TNM stage and cancer-specific survival of patients undergoing 
resection of colorectal cancer (P<0.001). B, Relationship between mGPS and cancer-specific survival of 
patients undergoing resection of colorectal cancer (P<0.001). C, Relationship between TNM stage and 
overall survival of patients undergoing resection of colorectal cancer (P<0.001). D, Relationship between 
mGPS and overall survival of patients undergoing resection of colorectal cancer (P<0.001). 
 
Figure 2. A, Relationship between mGPS and TNM stage and cancer-specific survival of patients 
undergoing resection of stage III colorectal cancer (P<0.001). B, Relationship between mGPS and overall 
survival of patients undergoing elective resection of colon cancer (P<0.001).  
 
Figure 3. A, Relationship between TNM stage and cancer-specific survival of patients undergoing elective 
resection of colon cancer (P<0.001). B, Relationship between mGPS and cancer-specific survival of patients 
undergoing elective resection of colon cancer (P<0.001). C, Relationship between TNM stage and overall 
survival of patients undergoing elective resection of colon cancer (P<0.001). D, Relationship between 
mGPS and overall survival of patients undergoing elective resection of colon cancer (P<0.001). 
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Table 1. The relationship between modified Glasgow Prognostic Score and clinicopathological 
characteristics in patients undergoing potentially curative resection of colorectal cancer 
    All  mGPS=0  mGPS=1  mGPS=2  
Clinicopathological 
Characteristic 
   n=1000 
(%) 
 n=635 
(%) 
 n=207 
(%) 
 n=158 
(%) 
P 
Age   
<65 
65-74 
>75 
  
330 (33) 
347 (35) 
323 (32) 
  
218 (34) 
238 (38) 
179 (28) 
  
66 (32) 
73 (35) 
68 (33) 
  
46 (29) 
36 (23) 
76 (48) 
0.001 
Sex   
Female 
Male 
  
452 (45) 
548 (55) 
  
274 (43) 
361 (57) 
  
102 (49) 
105 (51) 
  
76 (48) 
82 (52) 
0.137 
Presentation   
Elective 
Emergency 
  
913 (91) 
87 (9) 
  
610 (96) 
25 (4) 
  
174 (84) 
33 (16) 
  
129 (82) 
29 (18) 
<0.001 
Neoadjuvant therapy  a   
No 
Yes  
  
883 (88) 
98 (10) 
  
544 (88) 
77 (12) 
  
199 (97) 
7 (3) 
  
140 (91) 
14 (9) 
0.020 
Adjuvant therapy  b   
No 
Yes  
  
750 (75) 
248 (25) 
  
483 (76) 
151 (24) 
  
145 (70) 
62 (30) 
  
122 (78) 
35 (22) 
0.805 
Tumor site   
Colon 
Rectum 
  
656 (66) 
344 (34) 
  
380 (60) 
255 (40) 
  
152 (73) 
55 (27) 
  
124 (79) 
34 (22) 
<0.001 
T stage    
0 
1 
2 
3 
4 
  
13 (1) 
66 (7) 
112 (11) 
550 (55) 
259 (26) 
  
13 (2) 
56 (9) 
95 (15) 
354 (56) 
117 (18) 
  
0 (0) 
7 (3) 
11 (5) 
111 (54) 
78 (38) 
  
0 (0) 
3 (2) 
6 (4) 
85 (54) 
64 (41) 
<0.001 
N stage   
0 
1 
2 
  
618 (62) 
274 (27) 
108 (11) 
  
396 (62) 
182 (29) 
57 (9) 
 
 
 
118 (57) 
58 (28) 
31 (15) 
  
104 (66) 
34 (22) 
20 (13) 
0.470 
TNM stage   
0 
1 
2 
3 
 
 
 
13 (1) 
148 (15) 
457 (46) 
382 (38) 
  
0 (0) 
126 (20) 
257 (41) 
239 (38) 
  
0 (0) 
14 (7) 
104 (50) 
89 (43) 
  
0 (0) 
8 (5) 
96 (61) 
54 (34) 
0.001 
Less than 10 lymph 
nodes retrieved 
  
No 
Yes 
  
824 (82) 
176 (18) 
  
518 (82) 
117 (18) 
  
171 (83) 
36 (17) 
  
135 (85) 
23 (15) 
0.267 
Differentiation c   
Mod/well 
Poor 
  
894 (89) 
96 (10) 
  
584 (93) 
42 (7) 
  
181 (87) 
26 (13) 
  
129 (82) 
28 (18) 
<0.001 
Venous invasion   
No 
Yes 
  
493 (49) 
507 (51) 
  
312 (49) 
323 (51) 
  
108 (52) 
99 (48) 
   
73 (46) 
85 (54) 
0.747 
Margin involvement   
No 
Yes 
  
929 (93) 
71 (7) 
  
605 (95) 
30 (5) 
  
183 (88) 
24 (12) 
  
141 (89) 
17 (11) 
0.001 
Peritoneal involvement   
No 
  
773 (77) 
  
531 (84) 
  
138 (67) 
  
104 (66) 
<0.001 
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 a Data missing for 19 patients, b Data missing for 2 patients, c Data missing for 10 patients 
Yes 227 (23) 104 (16) 69 (33) 54 (34) 
Tumor perforation   
No 
Yes 
  
973 (97) 
26 (3) 
  
630 (99) 
5 (1) 
  
195 (94) 
11 (6) 
  
148 (94) 
10 (6) 
<0.001 
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Table 2. The relationship between clinicopathological characteristics and survival of patients undergoing potentially curative resection of colorectal 
cancer 
 
 Cancer-specific survival  Overall survival 
Clinicopathological Characteristic Univariate 
analysis 
P Multivariate 
analysis 
P  Univariate 
analysis 
P Multivariate 
analysis 
P 
Age (<65/ 65-74/ >75) 1.28 (1.09-1.50) 0.002 1.24 (1.06-1.46) 0.007  1.69 (1.50-1.91) <0.001 1.57 (1.39-1.79) <0.001 
Sex (Female/ male) 1.08 (0.84-1.40) 0.534 - -  1.14 (0.94-1.37) 0.189 - - 
Presentation (Elective/ emergency) 1.75 (1.20-2.55) 0.004 - 0.893  1.37 (1.01-1.88) 0.046 - 0.654 
Neoadjuvant therapy (No/ yes) 1.16 (0.76-1.78) 0.485 - -  0.84 (0.58-1.21) 0.349 - - 
Adjuvant therapy (No/ yes) 1.08 (0.81-1.44) 0.617 - -  0.75 (0.59-0.96) 0.020 0.73 (0.56-0.95) 0.017 
Tumor site (Colon/ rectum) 1.12 (0.86-1.45) 0.416 - -  0.96 (0.79-1.17) 0.694 - - 
T stage (0/ 1/ 2/ 3/ 4) 1.98 (1.63-2.40) <0.001 1.48 (1.21-1.82) <0.001  1.37 (1.20-1.56) <0.001 1.16 (1.01-1.33) 0.042 
N stage (0/ 1/ 2) 1.88 (1.60-2.21) <0.001 1.58 (1.33-1.88) <0.001  1.42 (1.25-1.62) <0.001 1.39 (1.21-1.60) <0.001 
Less than 10 lymph nodes retrieved 
(No/ yes) 
1.28 (0.95-1.72) 0.110 - -  1.15 (0.92-1.44) 0.227 - - 
Differentiation (Mod-well/ poor) 1.81 (1.25-2.63) 0.002 - 0.086  1.63 (1.22-2.17) 0.001 1.36 (1.02-1.82) 0.038 
Venous invasion (No/ yes) 1.69 (1.31-2.19) <0.001 - 0.094  1.36 (1.12-1.65) 0.002 - 0.066 
Margin involvement (No/ yes) 3.74 (2.67-5.23) <0.001 2.63 (1.86-3.73) <0.001  2.51 (1.87-3.36) <0.001 2.06 (1.52-2.80) <0.001 
Peritoneal involvement (No/ yes) 2.12 (1.63-2.76) <0.001 - 0.593  1.51 (1.22-1.86) <0.001 - 0.733 
Tumor perforation (No/ yes) 1.75 (0.93-3.29) 0.084 - -  1.48 (0.88-2.47) 0.138 - - 
mGPS (0/ 1/ 2) 1.51 (1.29-1.76) <0.001 1.28 (1.09-1.52) 0.003  1.43 (1.27-1.61) <0.001 1.28 (1.13-1.45) <0.001 
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Table 3a. The relationship between modified Glasgow Prognostic Score and five and ten-year cancer-specific survival in patients undergoing 
potentially curative resection of stage I-III colorectal cancer  
 mGPS = 0 
(CRP ≤10 mg/L) 
mGPS = 1 
(CRP >10mg/L and albumin ≥35 g/L) 
mGPS = 2 
(CRP >10mg/L and albumin <35g/L) 
All 
(mGPS = 0-2) 
 n 5-yr CSS % (SE) n 5-yr CSS % (SE) n 5-yr CSS % (SE) n  5-yr CSS % (SE) 
Stage 0 13 100 (0) 0 - 0 - 13 100 (0) 
Stage I 126  97 (2) 14  72 (14) 8  - 148 94 (2) 
Stage II 257  83 (3) 104 84 (4) 96 76 (5) 457 82 (2) 
Stage III 239  68 (4) 89  56 (6) 54  32 (8) 382 61 (3) 
All (Stage 0-III) 635 80 (2) 207 71 (3) 158 61 (5) 1000 75 (2) 
 n 10-yr CSS % (SE) n 10-yr CSS % (SE) n 10-yr CSS % (SE) n  10-yr CSS % (SE) 
Stage 0 13 100 (0) 0 - 0 - 13 100 (0) 
Stage I 126  86 (5) 14  57 (17) 8  - 148 83 (5) 
Stage II 257  75 (3) 104 76 (5) 96 61 (8) 457 73 (3) 
Stage III 239  56 (4) 89  53 (6) 54  32 (8) 382 52 (3) 
All (Stage 0-III) 635 70 (2) 207 65 (4) 158 52 (6) 1000 67 (2) 
CSS - cancer-specific survival. Survival not calculated if n<10 
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Table 3b. The relationship between modified Glasgow Prognostic Score and five and ten-year overall survival in patients undergoing potentially 
curative resection of stage I-III colorectal cancer 
 mGPS = 0 
(CRP ≤10 mg/L) 
mGPS = 1 
(CRP >10mg/L and albumin ≥35 g/L) 
mGPS = 2 
(CRP >10mg/L and albumin <35g/L) 
All 
(mGPS = 0-2) 
 n 5-yr OS % (SE) n 5-yr OS % (SE) n 5-yr OS % (SE) n  5-yr OS % (SE) 
Stage 0 13 92 (7) 0 - 0 - 13 92 (7) 
Stage I 126  87 (4) 14  59 (14) 8  - 148 80 (4) 
Stage II 257  74 (3) 104 74 (5) 96 57 (6) 457 70 (2) 
Stage III 239  59 (4) 89  45 (5) 54  26 (7) 382 51 (3) 
All (Stage 0-III) 635 70 (2) 207 60 (4) 158 46 (5) 1000 64 (2) 
 n 10-yr OS % (SE) n 10-yr OS % (SE) n 10-yr OS % (SE) n  10-yr OS % (SE) 
Stage 0 13 92 (7) 0 - 0 - 13 92 (7) 
Stage I 126  56 (8) 14  16 (14) 8  - 148 49 (7) 
Stage II 257  53 (4) 104 44 (6) 96 38 (7) 457 48 (3) 
Stage III 239  40 (4) 89  33 (5) 54  17 (7) 382 35 (3) 
All (Stage 0-III) 635 49 (3) 207 38 (4) 158 30 (5) 1000 43 (2) 
OS - overall survival. Survival not calculated if n<10 
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Table 4. The relationship between modified Glasgow Prognostic Score and clinicopathological 
characteristics in patients undergoing elective, potentially curative resection of colon cancer 
 a Data missing for 10 patients, b Data missing for 3 patients 
 
    mGPS=0  mGPS=1  mGPS=2  
Clinicopathological Characteristic    n=358 (%)  n=121 (%)  n=96 (%) P 
Age   
<65 
65-74 
>75 
  
112 (31) 
129 (36) 
117 (33) 
  
35 (29) 
39 (32) 
47 (39) 
  
25 (26) 
24 (25) 
47 (49) 
0.020 
Sex   
Female 
Male 
  
165 (46) 
193 (54) 
  
62 (51) 
59 (49) 
  
48 (50) 
48 (50) 
0.364 
Neoadjuvant therapy a   
No 
Yes 
  
348 (99) 
2 (1) 
  
119 (98) 
2 (2) 
  
93 (99) 
1 (1) 
0.456 
Adjuvant therapy   
No 
Yes 
  
271 (76) 
87 (24) 
  
89 (74) 
32 (26) 
  
76 (79) 
20 (21) 
0.640 
T stage    
1 
2 
3 
4 
  
32 (9) 
53 (15) 
196 (55) 
77 (22) 
  
1 (1) 
6 (5) 
68 (56) 
46 (38) 
  
2 (2) 
3 (3) 
54 (56) 
37 (39) 
<0.001 
N stage   
0 
1 
2 
  
231 (65) 
99 (28) 
28 (8) 
 
 
 
73 (60) 
34 (28) 
14 (12) 
  
66 (69) 
21 (22) 
9 (9) 
0.957 
TNM stage   
1 
2 
3 
 
 
 
76 (21) 
155 (43) 
127 (36) 
  
7 (6) 
66 (55) 
48 (40) 
  
4 (4) 
62 (65) 
30 (31) 
0.021 
Less than 10 lymph nodes retrieved   
No 
Yes 
  
295 (82) 
63 (18) 
  
97 (80) 
24 (20) 
  
85 (89) 
11 (11) 
0.286 
Differentiation b   
Mod/well 
Poor 
  
332 (93) 
24 (7) 
  
105 (87) 
16 (13) 
  
72 (76) 
23 (24) 
<0.001 
Venous invasion   
No 
Yes 
  
185 (52) 
173 (48) 
  
64 (53) 
57 (47) 
  
47 (49) 
49 (51) 
0.733 
Margin involvement   
No 
Yes 
  
349 (98) 
9 (3) 
  
113 (93) 
8 (7) 
  
89 (93) 
7 (7) 
0.015 
Peritoneal involvement   
No 
Yes 
  
287 (80) 
71 (20) 
  
80 (66) 
41 (34) 
  
67 (70) 
29 (30) 
0.005 
Tumor perforation   
No 
Yes 
  
356 (99) 
2 (1) 
  
116 (96) 
5 (4) 
  
91 (95) 
5 (5) 
0.001 
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Table 5a. The relationship between modified Glasgow Prognostic Score and five and ten-year cancer-specific survival in patients 
undergoing elective, potentially curative resection of stage I-III colon cancer  
 mGPS = 0 
(CRP ≤10 mg/L) 
mGPS = 1 
(CRP >10mg/L and albumin ≥35 g/L) 
mGPS = 2 
(CRP >10mg/L and albumin <35g/L) 
All 
(mGPS = 0-2) 
 n (%) 5-yr CSS % (SE) n (%) 5-yr CSS % (SE) n (%)  5-yr CSS % (SE) n  5-yr CSS % (SE) 
Stage I 76 100 (0) 7 - 4 - 87 96 (3) 
Stage II 155 89 (3) 66 86 (5) 62 78 (6) 283 86 (2) 
Stage III 127 75 (4) 48 53 (8) 30 37 (10) 205 63 (4) 
All (Stage I-III) 358 86 (2) 121 72 (5) 96 64 (6) 575  79 (2) 
 n (%) 10-yr CSS % (SE) n (%) 10-yr CSS % (SE) n (%)  10-yr CSS % (SE) n  10-yr CSS % (SE) 
Stage I 76 100 (0) 7 - 4 - 87 96 (3) 
Stage II 155 79 (4) 66 81 (6) 62 55 (11) 283 76 (3) 
Stage III 127 62 (6) 48 49 (8) 30 37 (10) 205 54 (5) 
All (Stage I-III) 358 76 (3) 121 68 (5) 96 49 (8) 575  70 (3) 
CSS - cancer-specific survival. Survival not calculated if n<10  
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Table 5b. The relationship between modified Glasgow Prognostic Score and five and ten-year overall survival in patients undergoing 
elective, potentially curative resection of stage I-III colon cancer 
 mGPS = 0 
(CRP ≤10 mg/L) 
mGPS = 1 
(CRP >10mg/L and albumin ≥35 g/L) 
mGPS = 2 
(CRP >10mg/L and albumin <35g/L) 
All 
(mGPS = 0-2) 
 n 5-yr OS %  (SE) n 5-yr OS %  (SE) n 5-yr OS %  (SE) n 5-yr OS %  (SE) 
Stage I 76 87 (5) 7 - 4 - 87 79 (5) 
Stage II 155 77 (4) 66 73 (6) 62 57 (7) 283 72 (3) 
Stage III 127 66 (5) 48 39 (7) 30 30 (9) 205 54 (4) 
All (Stage 0-III) 358 75 (3)  121 58 (5) 96 46 (6) 575  66 (2) 
 n 10-yr OS %  (SE) n 10-yr OS %  (SE) n 10-yr OS %  (SE) n 10-yr OS %  (SE) 
Stage I 76 53 (12) 7 - 4 - 87 44 (1) 
Stage II 155 56 (5) 66 42 (7) 62 30 (9) 283 47 (4) 
Stage III 127 50 (6) 48 24 (7) 30 17 (9) 205 38 (4) 
All (Stage 0-III) 358 54 (4) 121 32 (5) 96 24 (7) 575  43 (3) 
OS - overall survival. Survival not calculated if n<10 
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Table 6a. The relationship between modified Glasgow Prognostic Score, adjuvant chemotherapy use and five and ten-year overall 
survival in patients undergoing elective, potentially curative resection of stage III colon cancer 
 mGPS = 0 
(CRP ≤10 mg/L) 
mGPS = 1 
(CRP >10mg/L and albumin ≥35 g/L) 
mGPS = 2 
(CRP >10mg/L and albumin <35g/L) 
All 
(mGPS = 0-2) 
 n 5-yr CSS %  (SE) n 5-yr CSS %  (SE) n 5-yr CSS %  (SE) n 5-yr CSS %  (SE) 
Adjuvant therapy 64 91 (4) 23 61 (11) 8 - 95 79 (5) 
No adjuvant therapy 63 60 (7) 25 47 (11) 22 34 (11) 110 51 (5) 
All  127 75 (4) 48 53 (8) 30 37 (10) 205 63 (4) 
 n 10-yr CSS %  (SE) n 10-yr CSS %  (SE) n 10-yr CSS %  (SE) n 10-yr CSS %  (SE) 
Adjuvant therapy 64 72 (9) 23 53 (12) 8 - 95 64 (7) 
No adjuvant therapy 63 53 (8) 25 47 (11) 22 34 (11) 110 47 (6) 
All 127 62 (6) 48 49 (8) 30 37 (10) 205 54 (5) 
CSS – cancer-specific survival. Survival not calculated if n<10 
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Table 6b. The relationship between modified Glasgow Prognostic Score, ASCO high-risk pathological criteria and five and ten-year 
cancer-specific survival in patients undergoing elective, potentially curative resection of stage II colon cancer  
 mGPS = 0 
(CRP ≤10 mg/L) 
mGPS = 1 
(CRP >10mg/L and albumin ≥35 g/L) 
mGPS = 2 
(CRP >10mg/L and albumin <35g/L) 
All 
(mGPS = 0-2) 
 n (%) 5-yr CSS % (SE) n (%) 5-yr CSS % (SE) n (%)  5-yr CSS % (SE) n  5-yr CSS % (SE) 
Low risk 48 93 (4) 30 100 (0) 13 68 (13) 91 91 (3) 
High riska 84 85 (5) 27 84 (8) 37 78 (8) 148 83 (4) 
All (Low and high-risk) 132 88 (3) 57 92 (4) 50 75 (7) 239 86 (3) 
 n (%) 10-yr CSS % (SE) n (%) 10-yr CSS % (SE) n (%)  10-yr CSS % (SE) n  10-yr CSS % (SE) 
Low risk 48 88 (6) 30 89 (7) 13 68 (13) 91 85 (5) 
High risk 84 71 (7) 27 84 (8) 37 51 (14) 29 70 (5) 
All (Low and high-risk) 132 78 (5) 57 87 (5) 50 54 (12) 239 76 (4) 
a High-risk stage II colon cancer denoted by presence of one or more of the following: T4 tumor, lymph node yield <10 nodes, poor tumor differentiation, tumor perforation 
or venous invasion. CSS- cancer-specific survival 
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Table S1. The relationship between clinicopathological characteristics and survival of patients undergoing potentially curative, elective resection of 
colon cancer 
 Cancer-specific survival  Overall survival 
Clinicopathological Characteristic Univariate 
analysis 
P Multivariate 
analysis 
P  Univariate 
analysis 
P Multivariate 
analysis 
P 
Age (<65/ 65-74/ >75) 1.35 (1.08-1.69) 0.009 1.34 (1.07-1.68) 0.011  1.83 (1.55-2.15) <0.001 1.04 (1.03-1.06) <0.001 
Sex (Female/ male) 0.89 (0.63-1.27) 0.531 - -  1.00 (0.77-1.28) 0.967 - - 
Neoadjuvant therapy (No/ yes) 0.86 (0.12-6.17) 0.882 - -  0.40 (0.06-2.87) 0.364 - - 
Adjuvant therapy (No/ yes) 1.06 (0.71-1.60) 0.774 - -  0.61 (0.44-0.85) 0.004 0.65 (0.45-0.95) 0.025 
T stage (0/ 1/ 2/ 3/ 4) 2.44 (1.81-3.28) <0.001 1.77 (1.28-2.46) 0.001  1.36 (1.13-1.63) 0.001 - 0.383 
N stage (0/ 1/ 2) 2.09 (1.66-2.64) <0.001 1.86 (1.45-2.37) <0.001  1.42 (1.18-1.70) <0.001 1.62 (1.34-1.97) <0.001 
Less than 10 lymph nodes retrieved 
(No/ yes) 
1.02 (0.65-1.59) 0.946 - -  1.00 (0.73-1.36) 0.976 - - 
Differentiation (Mod-well/ poor) 1.49 (0.88-2.52) 0.140 - -  1.53 (1.06-2.20) 0.022 - 0.437 
Venous invasion (No/ yes) 1.88 (1.31-2.70) 0.001 - 0.151  1.31 (1.01-1.69) 0.041 - 0.140 
Margin involvement (No/ yes) 3.86 (2.17-6.87) <0.001 - 0.065  2.98 (1.86-4.77) <0.001 2.24 (1.38-3.62) 0.001 
Peritoneal involvement (No/ yes) 2.46 (1.72-3.53) <0.001 - 0.928  1.43 (1.09-1.88) 0.010 - 0.242 
Tumor perforation (No/ yes) 2.78 (1.14-6.82) 0.025 - 0.254  2.30 (1.13-4.65) 0.021 - 0.089 
mGPS (0/ 1/ 2) 1.76 (1.42-2.18) <0.001 1.61 (1.28-2.02) <0.001  1.64 (1.40-1.91) <0.001 1.52 (1.29-1.78) <0.001 
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